A crystalline variable hydrate of (S)-6-(4-(2-((3-(9H-carbazol-4-yloxy)-2hydroxypropyl)amino)-2-methylpropyl)phenoxy)-3pyridinecarbox amide hemisuccinate salt

Details for Australian Patent Application No. 2005275185 (hide)

Owner Eli Lilly and Company

Inventors Bush, Julie Kay

Agent Spruson & Ferguson

Pub. Number AU-B-2005275185

PCT Pub. Number WO2006/019835

Priority 60/590,251 22.07.04 US

Filing date 14 July 2005

Wipo publication date 23 February 2006

Acceptance publication date 23 June 2011

International Classifications

C07D 401/12 (2006.01) Heterocyclic compounds containing two or more hetero rings

A61K 31/4439 (2006.01)

A61P 3/04 (2006.01) Drugs for disorders of the metabolism

A61P 3/10 (2006.01) Drugs for disorders of the metabolism

Event Publications

8 February 2007 PCT application entered the National Phase

  PCT publication WO2006/019835 Priority application(s): WO2006/019835

23 June 2011 Application Accepted

  Published as AU-B-2005275185

20 October 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005275193-Methods and compositions for the administration of calcium chelators, bisphosphonates and/or citrate compounds and their pharmaceutical uses

2005275183-Oxazole derivatives as histamine H3 receptor agents, preparation and therapeutic uses